Dr. Winer Discusses Immunotherapy in Gynecologic Malignancies

Ira Winer, MD, PhD
Published: Tuesday, Apr 03, 2018



Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.

Immunotherapy has started to show promise in gynecologic malignancies. Winer says that it is being utilized in clinical trials of recurrent disease and in upfront trials. Currently, there is no way to select patients for these trials, Winer explains

Winer says that in a study of mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies, the implications for immune therapy were investigated.
SELECTED
LANGUAGE


Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.

Immunotherapy has started to show promise in gynecologic malignancies. Winer says that it is being utilized in clinical trials of recurrent disease and in upfront trials. Currently, there is no way to select patients for these trials, Winer explains

Winer says that in a study of mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies, the implications for immune therapy were investigated.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor TypesDec 31, 20181.5
Oncology Briefings™: New Frontiers in the Treatment of MSI High Endometrial CancerDec 31, 20181.0
Publication Bottom Border
Border Publication
x